<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR10.html">Part 10
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 10.20  Submission of documents to Division of Dockets   disclosure.
                            </h3>
                            <p class="depth0"><em>(a)</em> A submission to the Division of Dockets Management of a  petition, comment, objection, notice, compilation of information, or any  other document is to be filed in four copies except as otherwise  specifically provided in a relevant Federal Register notice or in  another section of this chapter. The Division of Dockets Management is  the agency custodian of these documents.</p><p class="depth0"><em>(b)</em>.</p><p class="depth0"><em>(c)</em> Information referred to or relied upon in a submission is to be  included in full and may not be incorporated by   reference, unless previously submitted in the same proceeding.</p><p class="depth0"><em>(1)</em> A copy of an article or other reference or source cited must be  included, except where the reference or source is:</p><p class="depth0"><em>(i)</em> A reported Federal court case;</p><p class="depth0"><em>(ii)</em> A Federal law or regulation;</p><p class="depth0"><em>(iii)</em> An FDA document that is routinely publicly available; or</p><p class="depth0"><em>(iv)</em> A recognized medical or scientific textbook that is readily  available to the agency.</p><p class="depth0"><em>(2)</em> If a part of the material submitted is in a foreign language, it  must be accompanied by an English translation verified to be complete  and accurate, together with the name, address, and a brief statement of  the qualifications of the person making the translation. A translation  of literature or other material in a foreign language is to be  accompanied by copies of the original publication.</p><p class="depth0"><em>(3)</em> Where relevant information is contained in a document also  containing irrelevant information, the irrelevant information is to be  deleted and only the relevant information is to be submitted.</p><p class="depth0"><em>(4)</em> Under Sec. 20.63 (a) and (b), the names and other information  that would identify patients or research subjects are to be deleted from  any record before it is submitted to the Division of Dockets Management  in order to preclude a clearly unwarranted invasion of personal privacy.</p><p class="depth0"><em>(5)</em> Defamatory, scurrilous, or intemperate matter is to be deleted  from a record before it is submitted to the Division of Dockets  Management.</p><p class="depth0"><em>(6)</em> The failure to comply with the requirements of this part or with  Sec. 12.80 or Sec. 13.20 will result in rejection of the submission  for filing or, if it is filed, in exclusion from consideration of any  portion that fails to comply. If a submission fails to meet any  requirement of this section and the deficiency becomes known to the  Division of Dockets Management, the Division of Dockets Management shall  not file the submission but return it with a copy of the applicable  regulations indicating those provisions not complied with. A deficient  submission may be corrected or supplemented and subsequently filed. The  office of the Division of Dockets Management does not make decisions  regarding the confidentiality of submitted documents.</p><p class="depth0"><em>(d)</em> The filing of a submission means only that the Division of  Dockets Management has identified no technical deficiencies in the  submission. The filing of a petition does not mean or imply that it  meets all applicable requirements or that it contains reasonable grounds  for the action requested or that the action requested is in accordance  with law.</p><p class="depth0"><em>(e)</em> All submissions to the Division of Dockets Management will be  considered as submitted on the date they are postmarked or, if delivered  in person during regular business hours, on the date they are delivered,  unless a provision in this part, an applicable Federal Register notice,  or an order issued by an administrative law judge specifically states  that the documents must be received by a specified date, e.g., Sec.  10.33(g) relating to a petition for reconsideration, in which case they  will be considered submitted on the date received.</p><p class="depth0"><em>(f)</em> All submissions are to be mailed or delivered in person to the  Division of Dockets Management, Food and Drug Administration, 5630  Fishers Lane, rm. 1061, Rockville, MD 20852.</p><p class="depth0"><em>(g)</em> FDA ordinarily will not acknowledge or give receipt for  documents, except:</p><p class="depth0"><em>(1)</em> Documents delivered in person or by certified or registered mail  with a return receipt requested; and</p><p class="depth0"><em>(2)</em> Petitions for which acknowledgment of receipt of filing is  provided by regulation or by customary practice, e.g., Sec. 10.30(c)  relating to a citizen petition.</p><p class="depth0"><em>(h)</em> Saturdays, Sundays, and Federal legal holidays are included in  computing the time allowed for the submission of documents, except that  when the time for submission expires on a Saturday, Sunday, or Federal  legal holiday, the period will be extended to include the next business  day.</p><p class="depth0"><em>(i)</em> All submissions to the Division of Dockets Management are  representations that, to the best of the knowledge, information, and  belief of the person making the submission, the statements made in the  submission are true and accurate. All submissions are   subject to the False Reports to the Government Act (18 U.S.C. 1001)  under which a willfully false statement is a criminal offense.</p><p class="depth0"><em>(j)</em> The availability for public examination and copying of  submissions to the Division of Dockets Management is governed by the  following rules:</p><p class="depth0"><em>(1)</em> Except to the extent provided in paragraphs (j)(2) and (3) of  this section, the following submissions, including all supporting  material, will be on public display and will be available for public  examination between 9 a.m. and 4 p.m., Monday through Friday. Requests  for copies of submissions will be filed and handled in accordance with  subpart C of part 20:</p><p class="depth0"><em>(i)</em> Petitions.</p><p class="depth0"><em>(ii)</em> Comments on petitions, on documents published in the Federal  Register, and on similar public documents.</p><p class="depth0"><em>(iii)</em> Objections and requests for hearings filed under part 12.</p><p class="depth0"><em>(iv)</em> Material submitted at a hearing under Sec. 12.32(a)(2) and  parts 12, 13, and 15.</p><p class="depth0"><em>(v)</em> Material placed on public display under the regulations in this  chapter, e.g., agency guidance documents developed under Sec. 10.115.</p><p class="depth0"><em>(2)</em></p><p class="depth0"><em>(i)</em> Material prohibited from public disclosure under Sec. 20.63  (clearly unwarranted invasion of personal privacy) and, except as  provided in paragraph (j)(3) of this section, material submitted with  objections and requests for hearing filed under part 12, or at a hearing  under part 12 or part 13, or an alternative form of public hearing  before a public advisory committee or a hearing under Sec. 12.32(a) (2)  or (3), of the following types will not be on public display, will not  be available for public examination, and will not be available for  copying or any other form of verbatim transcription unless it is  otherwise available for public disclosure under part 20:</p><p class="depth0"><em>(a)</em> Safety and effectiveness information, which includes all studies  and tests of an ingredient or product on animals and humans and all  studies and tests on the ingredient or product for identity, stability,  purity, potency, bioavailability, performance, and usefulness.</p><p class="depth0"><em>(b)</em> A protocol for a test or study.</p><p class="depth0"><em>(c)</em> Manufacturing methods or processes, including quality control  procedures.</p><p class="depth0"><em>(d)</em> Production, sales distribution, and similar information, except  any compilation of information aggregated and prepared in a way that  does not reveal confidential information.</p><p class="depth0"><em>(e)</em> Quantitative or semiquantitative formulas.</p><p class="depth0"><em>(f)</em> Information on product design or construction.</p><p class="depth0"><em>(ii)</em> Material submitted under paragraph (j)(2) of this section is to  be segregated from all other submitted material and clearly so marked. A  person who does not agree that a submission is properly subject to  paragraph (j)(2) may request a ruling from the Associate Commissioner  for Public Affairs whose decision is final, subject to judicial review  under Sec. 20.48.</p><p class="depth0"><em>(3)</em> Material listed in paragraph (j)(2)(i) (a) and (b) of this  section may be disclosed under a protective order issued by the  administrative law judge or other presiding officer at a hearing  referenced in paragraph (j)(2)(i). The administrative law judge or  presiding officer shall permit disclosure of the data only in camera and  only to the extent necessary for the proper conduct of the hearing. The  administrative law judge or presiding officer shall direct to whom the  information is to be made available (e.g., to parties or participants,  or only to counsel for parties or participants), and persons not  specifically permitted access to the data will be excluded from the in  camera part of the proceeding. The administrative law judge or other  presiding officer may impose other conditions or safeguards. The limited  availability of material under this paragraph does not constitute prior  disclosure to the public as defined in Sec. 20.81, and no information  subject to a particular order is to be submitted to or received or  considered by FDA in support of a petition or other request from any  other person.  [44 FR 22323, Apr. 13, 1979, as amended at 46 FR 8455, Jan. 27, 1981; 49  FR 7363, Feb. 29, 1984; 54 FR 9034, Mar. 3, 1989; 59 FR 14363, Mar. 28,  1994; 64 FR 69190, Dec. 10, 1999; 65 FR 56477, Sept. 19, 2000; 66 FR  56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 25285, May 12,  2003]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ❤ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
